Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBotanix Pharmaceuticals Ltd

Botanix Pharmaceuticals Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.01 AUD -0.00 ( 9.09%)
Last update at 2026-11-06T05:10:00Z
VOLUME
23693450
Market Cap
30.39M

Momentum Score

…

Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older. It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatment of serious acne in adults and teenagers; BTX 1702 that is in Phase 1b/2 clinical trial to treat papulopustular rosacea; BTX 1204A for treating atopic dermatitis; and BTX 1801, which has been completed Phase 2a clinical trial for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus. The company was incorporated in 1984 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.15
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Botanix Pharmaceuticals is an Australian clinical-stage company developing topical dermatology therapies using a proprietary transdermal delivery platform and synthetic cannabidiol compounds. Long-term growth depends on successful clinical trials and regulatory approvals, licensing or commercial partnerships, and adoption in large dermatology markets such as acne and antimicrobial applications. Investors may find it attractive for exposure to a platform-based approach that could support multiple indications.

Material risks include high clinical and regulatory execution risk, ongoing funding requirements and dilution, reliance on platform intellectual property, and competition from established dermatology products.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
33.80M
Revenue Per Share
0.02
Gross Profit TTM
19.45M
Debt / Equity
0.23
ROE
-96.35%
Net Debt
-21.89M
ROCE
-92.42%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -69.77M -86.40M -13.87M -9.15M -13.17M
Net income -69.77M -86.40M -13.87M -9.15M -13.17M
Selling general administrative - 9.09M 6.65M 3.04M 3.56M
Selling and marketing expenses - 38.46M 0.33M - -
Gross profit -59.43M 2.02M -6.12M -5.62M 0.10M
Reconciled depreciation - 2.26M 0.07M 0.11M 0.14M
Ebit - -82.91M -15.33M -9.07M -13.13M
Ebitda -69.31M -80.65M -15.25M -8.96M -12.99M
Depreciation and amortization - 2.26M 0.07M 0.11M 0.14M
Operating income -69.31M -80.79M -15.73M -9.13M -13.13M
Other operating expenses 103.82M 86.58M 16.06M -1.46M 15.94M
Interest expense 2.84M 5.37M 0.01M 0.08M 0.04M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 1.88M 0.08M 0.09M 0.04M
Net interest income - -0.09M 0.07M -0.02M -0.00M
Income tax expense - - -1.47M 3.74M 2.81M
Total revenue 34.51M 5.79M 0.60M 0.10M 0.10M
Total operating expenses 9.88M 82.81M 9.34M 12.90M 15.94M
Cost of revenue 93.95M 3.77M 7.15M 5.73M -
Total other income expense net -0.46M -5.60M 1.86M 3.66M 2.77M
Net income from continuing ops - -86.40M -13.87M -9.15M -13.17M
Net income applicable to common shares - -86.40M -13.87M -9.15M -13.17M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 105.98M 129.10M 112.46M 24.84M 14.04M
Intangible assets 24.88M 28.12M - 10.73M 3.30M
Other current assets 5.65M - 1.57M 0.09M 0.03M
Total liab 42.45M 47.80M 3.73M 1.88M 5.89M
Total stockholder equity 63.52M 81.30M 108.73M 22.95M 8.15M
Deferred long term liab - - - 3.87M -
Other current liab 10.83M - 1.00M 0.49M 1.20M
Common stock - - 188.32M 93.49M 71.48M
Capital stock - 226.30M - 93.49M 71.48M
Retained earnings -246.96M -177.19M -90.79M -76.92M -67.77M
Other assets - - 0.00M 3.94M 0.06M
Cash 36.63M 64.97M 79.31M 10.25M 7.29M
Total current liabilities 30.98M 24.92M 3.73M 1.88M 5.89M
Current deferred revenue - - - - -1.11M
Net debt -21.89M - -79.31M -10.25M -7.16M
Short term debt 14.29M - - 0.00M 0.12M
Short long term debt - 8.82M - - -
Short long term debt total 14.74M - - - 0.12M
Other stockholder equity 310.48M - - -16.57M -3.71M
Property plant equipment - - - 0.07M 0.18M
Total current assets 80.28M 99.59M 82.90M 13.98M 10.50M
Long term investments - - - - 0.06M
Net tangible assets - - - 16.10M 4.86M
Net receivables 6.64M 2.85M 0.82M 0.49M 0.14M
Long term debt - 22.07M - - -
Inventory 31.35M 28.08M 1.21M 3.15M 3.04M
Accounts payable 5.86M 8.87M 2.73M 1.39M 5.67M
Accumulated other comprehensive income - - 11.20M 6.38M 4.44M
Non currrent assets other - - 29.49M 0.06M 0.06M
Non current assets total 25.70M 29.51M 29.56M 10.86M 3.54M
Capital lease obligations - 1.22M - - 0.12M
Long term debt total - - - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -1.05M -18.00M -7.05M -2.92M
Change to liabilities - - - -4.04M 4.65M
Total cashflows from investing activities -0.41M -1.05M -18.00M -7.05M -2.92M
Net borrowings - 27.63M - -0.12M -0.15M
Total cash from financing activities 36.58M 65.36M 95.10M 22.03M -0.15M
Net income -69.77M -86.40M -13.87M -9.15M -13.17M
Change in cash -28.34M -14.34M 69.06M 2.96M -14.27M
Begin period cash flow 64.97M 79.31M 10.25M 7.29M 21.55M
End period cash flow 36.63M 64.97M 79.31M 10.25M 7.29M
Total cash from operating activities -64.60M -78.58M -8.13M -12.07M -11.18M
Issuance of capital stock - 40.46M 100.85M 23.59M -
Depreciation - 7.37M 0.07M 0.11M 0.14M
Other cashflows from investing activities -0.41M -0.76M -17.89M - -
Dividends paid - - - -1.85M 20.30M
Change to inventory -4.95M -26.87M 1.68M -0.10M -3.04M
Change to account receivables -5.34M -4.16M -2.34M -0.41M -0.10M
Sale purchase of stock - -2.54M -5.76M -1.44M -1.44M
Other cashflows from financing activities -0.26M 27.63M -18.00M 3.58M -0.15M
Change to netincome - - - 1.52M 1.84M
Capital expenditures 0.00M 0.29M 18.00M 7.05M 2.92M
Change in working capital -8.42M -31.03M 1.28M -0.51M -3.14M
Stock based compensation - 20.52M 4.39M 1.52M 0.33M
Other non cash items 13.59M 10.95M -0.00M -3.03M 1.84M
Free cash flow -64.60M -78.87M -26.13M -19.13M -14.11M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BOT
Botanix Pharmaceuticals Ltd		 -0.00
9.09%		 0.01 - 5.84 0.90 0.39 0.41 -11.08
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Botanix Pharmaceuticals Ltd

Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older. It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatment of serious acne in adults and teenagers; BTX 1702 that is in Phase 1b/2 clinical trial to treat papulopustular rosacea; BTX 1204A for treating atopic dermatitis; and BTX 1801, which has been completed Phase 2a clinical trial for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus. The company was incorporated in 1984 and is based in Melbourne, Australia.

Tower 5, Collins Square, Melbourne, VIC, Australia, 3008

61 8 6555 2945

https://www.botanixpharma.com

Name Title Year Born
Mr. Vincent P. Ippolito MD & Exec. Chairman 1959
Dr. Howie McKibbon Chief Operating Officer NA
Dr. Henry William Bosch BA, Ph.D. Chief Scientific Officer & Exec. Director NA
Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB Exec. Director 1973
Dr. Clarence L. Young M.D. Chief Medical Officer 1956
Ms. Lynda Berne Head of Commercial NA
Dr. Jack Hoblitzell Ph.D. Sr. VP of Pharmaceutical Devel. NA
Dr. Patricia S. Walker M.D., Ph.D. Chief Medical Adviser 1959
Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA Company Sec. NA
Mr. Vincent P. Ippolito MD & Executive Chairman 1959

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…